EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

Jason A Chesney iD, Igor Puzanov iD, Frances A Collichio, Parminder Singh, Mohammed M Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore Logan, Axel Hauschild und 4 weitere

Journal for ImmunoTherapy of Cancer · 2023-05 · 11 (5) · e006270

DOI: 10.1136/jitc-2022-006270 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 04.05.2023. Verfasst von Jason A Chesney und 15 weiteren Autor:innen. Beteiligte Einrichtung: J. Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA jason.chesney@louisville.edu. Hauptthemen laut MEDLINE: Melanoma, Oncolytic Virotherapy, Herpesvirus 1, Human, Oncolytic Viruses. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Amgen Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma. Here, we report the 5-year outcomes from a randomized phase II study. These data provide the longest efficacy and safety follow-up for patients with melanoma treated with a combination of an oncolytic virus and a checkpoint inhibitor. Eligible patients with unresectable stage IIIB‒IV melanoma were randomized 1:1 to receive T-VEC plus ipilimumab or ipilimumab alone. T-VEC was administered intralesionally at 10 6 plaque-forming units (PFU)/mL in week 1, followed by 10 8 PFU/mL in week 4 and every 2 weeks thereafter. Ipilimumab (3 mg/kg every 3 weeks; ≤4 doses) was administered intravenously starting at week 1 in the ipilimumab arm and week 6 in the combination arm. The primary end point was investigator-assessed objective response rate (ORR) per immune-related response criteria; key secondary end points included durable response rate (DRR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Overall, 198 patients were randomized to receive the combination (n=98) or ipilimumab (n=100). The combination improved the ORR versus ipilimumab (35.7% vs 16.0%; OR 2.9; 95% CI 1.5 to 5.7; p=0.003). DRR was 33.7% and 13.0% (unadjusted OR 3.4; 95% CI 1.7 to 7.0; descriptive p=0.001), respectively. Among the objective responders, the median DOR was 69.2 months (95% CI 38.5 to not estimable) with the combination and was not reached with ipilimumab. Median PFS was 13.5 months with the combination and 6.4 months with ipilimumab (HR 0.78; 95% CI 0.55 to 1.09; descriptive p=0.14). Estimated 5-year OS was 54.7% (95% CI 43.9 to 64.2) in the combination arm and 48.4% (95% CI 37.9 to 58.1) in the ipilimumab arm. Forty-seven (48.0%) and 65 (65.0%) patients in the combination and ipilimumab arms, respectively, received subsequent therapies. No new safety signals were reported. At the 5-year follow-up, the improved response rates observed with T-VEC plus ipilimumab were durable. This is the first randomized controlled study of the combination of an oncolytic virus and a checkpoint inhibitor that meets its primary end point.Trial registration number: NCT01740297 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaOncolytic VirotherapyHerpesvirus 1, HumanOncolytic VirusesHumansIpilimumabBiological Products

Stichwörter der Autor:innen

immunotherapymelanomaoncolytic virotherapyoncolytic viruses

Substanzen

Ipilimumabtalimogene laherparepvecBiological Products

Autor:innen und Institutionen

  • J. Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA jason.chesney@louisville.edu.
  • Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Mayo Clinic, Phoenix, Arizona, USA.
  • University of Iowa Hospitals and Clinics, Iowa City, lowa, USA.
  • University of California Los Angeles School of Medicine, Los Angeles, California, USA.

ORCID-Profile: Jason A Chesney, Igor Puzanov

Förderung

  • NCI NIH HHS
  • Amgen Inc

Zitieren

APA

Chesney, J. A., Puzanov, I., Collichio, F. A., Singh, P., Milhem, M. M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., Logan, T., Hauschild, A., Lebbé, C., Joshi, H., Snyder, W., & Mehnert, J. M. (2023). Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. Journal for ImmunoTherapy of Cancer, 11(5), e006270. https://doi.org/10.1136/jitc-2022-006270

Vancouver

Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, et al. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. Journal for ImmunoTherapy of Cancer. 2023;11(5):e006270. doi:10.1136/jitc-2022-006270

BibTeX
@article{Chesney2023,
  author = {Chesney, Jason A and Puzanov, Igor and Collichio, Frances A and Singh, Parminder and Milhem, Mohammed M and Glaspy, John and Hamid, Omid and Ross, Merrick and Friedlander, Philip and Garbe, Claus and Logan, Theodore and Hauschild, Axel and Lebbé, Celeste and Joshi, Harshada and Snyder, Wendy and Mehnert, Janice M},
  title = {Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {5},
  pages = {e006270},
  doi = {10.1136/jitc-2022-006270}
}
Kostenlos starten →